Aviso: Este sitio agrega datos públicos oficiales de la FDA, ClinicalTrials.gov, PubMed y SEC EDGAR solo como referencia general. No constituye asesoramiento médico, diagnóstico, recomendaciones de tratamiento ni asesoramiento de inversión.

PubMed

Risk management and regulations for lower limb medical exoskeletons: a review.

PMID: 28533700 ·

Y, o, n, g, t, i, a, n, , H, e, ;, , D, a, v, i, d, , E, g, u, r, e, n, ;, , T, r, i, e, u, , P, h, a, t, , L, u, u, ;, , J, o, s, e, , L, , C, o, n, t, r, e, r, a, s, -, V, i, d, a, l

RevistaMedical devices (Auckland, N.Z.)
Año
PMID28533700

Resumen

Gait disability is a major health care problem worldwide. Powered exoskeletons have recently emerged as devices that can enable users with gait disabilities to ambulate in an upright posture, and potentially bring other clinical benefits. In 2014, the US Food and Drug Administration approved marketing of the ReWalk™ Personal Exoskeleton as a class II medical device with special controls. Since then, Indego™ and Ekso™ have also received regulatory approval. With similar trends worldwide, this ind

Fuente oficial

Ver en PubMed →

Datos obtenidos de PubMed / NCBI. Para consultar el texto completo y la información más reciente, remítase siempre al registro oficial.

↑